This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1981 Jan;11(1):89-91.

doi: 10.1111/j.1365-2125.1981.tb01108.x.

Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver

D S Davies, G C Kahn, S Murray, M J Brodie, A R Boobis

PMID: 7213514
PMCID: PMC1401705
DOI: 10.1111/j.1365-2125.1981.tb01108.x

Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver

D S Davies et al. Br J Clin Pharmacol. 1981 Jan.

. 1981 Jan;11(1):89-91.

doi: 10.1111/j.1365-2125.1981.tb01108.x.

Authors

D S Davies, G C Kahn, S Murray, M J Brodie, A R Boobis

PMID: 7213514
PMCID: PMC1401705
DOI: 10.1111/j.1365-2125.1981.tb01108.x

No abstract available

PubMed Disclaimer

Similar articles

Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.
Bertilsson L, Eichelbaum M, Mellström B, Säwe J, Schulz HU, Sjöqvist F. Bertilsson L, et al. Life Sci. 1980 Nov 3;27(18):1673-7. doi: 10.1016/0024-3205(80)90642-6. Life Sci. 1980. PMID: 7442467 No abstract available.
Deficient metabolism of debrisoquine and sparteine.
Inaba T, Otton SV, Kalow W. Inaba T, et al. Clin Pharmacol Ther. 1980 Apr;27(4):547-9. doi: 10.1038/clpt.1980.77. Clin Pharmacol Ther. 1980. PMID: 7357813
Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
Danhof M, Idle JR, Teunissen MW, Sloan TP, Breimer DD, Smith RL. Danhof M, et al. Pharmacology. 1981;22(6):349-58. doi: 10.1159/000137515. Pharmacology. 1981. PMID: 7267701
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
Lennard MS, Tucker GT, Woods HF. Lennard MS, et al. Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001. Clin Pharmacokinet. 1986. PMID: 2868819 Review.
Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.
Spina E, Steiner E, Dumont E, Dahlqvist R. Spina E, et al. Psychopharmacol Ser. 1989;7:201-5. doi: 10.1007/978-3-642-74430-3_21. Psychopharmacol Ser. 1989. PMID: 2687858 Review. No abstract available.

See all similar articles

Cited by

Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.
Kahn GC, Boobis AR, Murray S, Brodie MJ, Davies DS. Kahn GC, et al. Br J Clin Pharmacol. 1982 May;13(5):637-45. doi: 10.1111/j.1365-2125.1982.tb01430.x. Br J Clin Pharmacol. 1982. PMID: 7082530 Free PMC article.
Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.
Veronese ME, McLean S. Veronese ME, et al. Eur J Clin Pharmacol. 1991;40(6):547-52. doi: 10.1007/BF00279967. Eur J Clin Pharmacol. 1991. PMID: 1884734
The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition.
Devonshire HW, Kong I, Cooper M, Sloan TP, Idle JR, Smith RL. Devonshire HW, et al. Br J Clin Pharmacol. 1983 Aug;16(2):157-66. doi: 10.1111/j.1365-2125.1983.tb04980.x. Br J Clin Pharmacol. 1983. PMID: 6615690 Free PMC article.
The relationship between the acetylator and the sparteine hydroxylation polymorphisms.
Harmer D, Evans DA, Eze LC, Jolly M, Whibley EJ. Harmer D, et al. J Med Genet. 1986 Apr;23(2):155-6. doi: 10.1136/jmg.23.2.155. J Med Genet. 1986. PMID: 3712391 Free PMC article.
Oxidation phenotype and the metabolism and action of beta-blockers.
Lennard MS. Lennard MS. Klin Wochenschr. 1985 Apr 1;63(7):285-92. doi: 10.1007/BF01731972. Klin Wochenschr. 1985. PMID: 2860267 Review.

See all "Cited by" articles

References

1. Anal Chem. 1976 May;48(6):807-9 - PubMed
1. Lancet. 1977 Sep 17;2(8038):584-6 - PubMed
1. Lancet. 1977 Oct 1;2(8040):718 - PubMed
1. Br Med J. 1978 Sep 2;2(6138):655-7 - PubMed
1. Br J Pharmacol. 1979 Jul;66(3):428P - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources